Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications
DOI 10.1038/ncomms10501

Cited by (1,000)

Items 901–1,000 of 1,000

  1. The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy
    Zakia Akter, Narges Salamat, Md. Yousuf Ali, Zhang Li · 2023 · Frontiers in Oncology
  2. Novel Therapeutic Options for Small Cell Lung Cancer
    Stefania Canova, Benedetta Trevisan, Maria Ida Abbate, Francesca Colonese, Luca Sala, Alice Baggi, Sofia Paola Bianchi, Anna Grazia D'Agostino, Diego Luigi Cortinovis · 2023 · Current Oncology Reports
  3. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
    Julio F. Inocencio, Stefan Mitrasinovic, Mohammad Asad, Ian F. Parney, Xingxing Zang, Benjamin T. Himes · 2024 · Frontiers in Immunology
  4. Saffron improves the efficacy of immunotherapy for colorectal cancer through the IL-17 signaling pathway
    Siqi Feng, Shiying Li, Zhonghua Wu, Yun Li, Tingting Wu, Zhangjie Zhou, Xinhua Liu, Jian Chen, Shujuan Fu, Zhiying Wang et al. · 2024 · Journal of Ethnopharmacology
  5. Immunotherapeutic Strategies in Non-Small-Cell Lung Cancer: The Present and the Future
    Christi M. J. Steendam, Floris F. Dammeijer, Joachim G.J.V. Aerts, Robin Cornelissen · 2017 · Immunotherapy
  6. Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
    Clémence Granier, Emeline Vinatier, Elia Colin, Marion Mandavit, Charles Dariane, Virginie Verkarre, Lucie Biard, Rami M. El Zein, Corinne Lesaffre, Isabelle Galy–Fauroux et al. · 2018 · Journal of Visualized Experiments
  7. Immunotherapy for Glioblastoma: Playing Chess, Not Checkers
    Christopher Mitchell Jackson, Michael K. Lim · 2018 · Clinical Cancer Research
  8. Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
    Jonathan Chee, Mark W Watson, Abha Chopra, Bella Nguyen, Alistair Cook, Jenette Creaney, Willem Joost Lesterhuis, Bruce W. S. Robinson, Gary Lee, Anna K. Nowak et al. · 2018 · BMC Research Notes
  9. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
    Arsela Prelaj, Chiara Carlotta Pircher, Giacomo Massa, Valentino Martelli, Giulia Corrao, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Giulia Galli, Alessandro De Toma et al. · 2021 · Cancers
  10. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
    Jessica Waibl Polania, Emily Lerner, Daniel S. Wilkinson, Alexandra M. Hoyt-Miggelbrink, Peter Edward Fecci · 2021 · Frontiers in Immunology
  11. Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases
    Misato Ito, Kosaku Mimura, Shotaro Nakajima, Katsuharu Saito, Aung Kyi Thar Min, Hirokazu Okayama, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Mikio Ohtsuka et al. · 2022 · Cancer Immunology Immunotherapy
  12. Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
    Kristian Taipale, Siri Tähtinen, Riikka Havunen, Anniina Koski, Ilkka Liikanen, Päivi I. Pakarinen, Riitta Koivisto-Korander, Matti Kankainen, Timo K. Joensuu, Anna Kanerva et al. · 2018 · Oncotarget
  13. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma
    Nazanin Majd, John de Groot · 2019 · Expert Opinion on Pharmacotherapy
  14. Targeting novel inhibitory receptors in cancer immunotherapy
    Quanquan Ding, Joë-Marc Chauvin, Hassane M. Zarour · 2020 · Seminars in Immunology
  15. Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades
    Dinglin Liu, Haoyue Xiao, Ying Xiang, Dian Zhong, Yuchen Liu, Yunfei Wang, Weijia Zhang · 2025 · Journal of Cancer
  16. SOX9 has distinct roles in the formation and progression of different non‐small cell lung cancer histotypes
    Jie Bao, Katja Maria Närhi, Ana Teodòsio, Annabrita Hemmes, Nora M Linnavirta, Mikko Ilari Mäyränpää, Kaisa Salmenkivi, John P. C. Le Quesne, Emmy W. Verschuren · 2021 · The Journal of Pathology
  17. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
    Ingunn M. Stromnes, Ayaka Hulbert, Meagan R. Rollins, Ryan Basom, Jeffrey J. Delrow, Patrick Bonson, Adam L. Burrack, Sunil R. Hingorani, Philip D. Greenberg · 2022 · Journal for ImmunoTherapy of Cancer
  18. PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival
    Oscar Jimenez, Tamara Mangiaterra, Sandra Lorena Colli, Mercedes García Lombardi, María Victoria Preciado, Elena De Matteo, Paola Chabay · 2022 · Frontiers in Oncology
  19. Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy
    Morgane Denis, Doriane Mathé, Manon Micoud, Pierre‐Antoine Choffour, Chloé Grasselly, Eva‐Laure Matera, Charles Dumontet · 2023 · Frontiers in Immunology
  20. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools
    Akbar Hasanzadeh, Arefeh Ebadati, Lida Dastanpour, Amir Reza Aref, Parham Sahandi Zangabad, Alireza Kalbasi, Xiaofeng Dai, Geeta Mehta, Amir Ghasemi, Yousef Fatahi et al. · 2023 · ACS Pharmacology & Translational Science
  21. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
    J. Hilton, P. Ott, A. Hansen, Zujun Li, M. Mathew, C. Messina, V. Dave, Xiao-lin Ji, N. Karpinich, Steven Hirschfeld et al. · 2024 · Cancer Immunology and Immunotherapy
  22. Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
    Jordan A. Stinson, Matheus Moreno P. Barbosa, Allison M. Sheen, Noor Momin, Elizabeth Fink, Jordan Hampel, Kim A. Selting, Rebecca L. Kamerer, Keith L. Bailey, Karl Dane Wittrup et al. · 2024 · Clinical Cancer Research
  23. Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
    Iulia Giuroiu, Jeffrey S. Weber · 2017 · The Cancer Journal
  24. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
    K. Hladíková, S. Partlová, V. Koucký, J. Bouček, J. Fonteneau, M. Zábrodský, R. Tachezy, M. Grega, R. Špíšek, A. Fialová · 2018 · Oral Oncology
  25. The 5-Ws of immunotherapy in head and neck cancer
    Andrea Botticelli, Silvia Mezi, Giulia Pomati, Bruna Cerbelli, Christiana Di Rocco, Sasan Amirhassankhani, Grazia Sirgiovanni, Mario Alberto Occhipinti, Valerio Maria Napoli, Alessandra Emiliani et al. · 2020 · Critical Reviews in Oncology/Hematology
  26. Combination therapy with anti‐T‐cell immunoglobulin and mucin‐domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma
    K.P. Kim, Hye Won Lee, Jinsil Seong · 2020 · Journal of Gastroenterology and Hepatology
  27. Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review)
    Lin-Rui Ma, Jiaxin Li, Ling Long Tang, Runze Li, Jia‐Shun Yang, Ao Sun, Elaine Lai‐Han Leung, Peiyu Yan · 2021 · Oncology Letters
  28. A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease
    Jiahui Wang, Jinsheng Hong, Feiyu Yang, Fangming Liu, Xiangdong Wang, Zan Shen, Duojiao Wu · 2021 · Cell Biology and Toxicology
  29. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma
    Dong Cai, Zhibo Zhao, Jie‐Jun Hu, Xin Dai, Guo‐Chao Zhong, Jianping Gong, Feng Qi · 2022 · Frontiers in Surgery
  30. PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials
    Miles M. Hsu, Arjun Vasant Balar · 2019 · Clinical Genitourinary Cancer
  31. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation
    Tao Zhang, Wenyue Zhu, Yiwei Zhao, Wing Ching Cheung, Yingyu Liu, Xiaoyan Chen, Yan Du, Kam Tong Leung, David Yiu Leung Chan, Chi Chiu Wang et al. · 2020 · Fertility and Sterility
  32. Correction: A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival
    Tolga Turan, Sarah Kongpachith, Kyle D. Halliwill, Jessica P Roelands, Wouter Hendrickx, Francesco Maria Marincola, Thomas J. Hudson, Howard J. Jacob, Davide Bedognetti, Josue A. Samayoa et al. · 2020 · British Journal of Cancer
  33. Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
    Peng Gao, Xiao Li, Zhenyu Duan, Yang Wang, Yinggang Li, Jing Wang, Kui Luo, Jie Chen · 2025 · MedComm
  34. Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation
    Thomas Zachary Benton, Catherine M. Mills, Jonathan M. Turner, Megan J. Francis, Dalan J. Solomon, Pieter B. Burger, Yuri Karl Peterson, Nathan G. Dolloff, André S. Bachmann, Patrick M. Woster · 2021 · RSC Advances
  35. Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity
    Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo · 2021 · Journal of Histochemistry & Cytochemistry
  36. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer
    Na Li, Geng Wang, Xin Hou, Risheng Tai, Shaogang Huang, Zhize He, Lei Lei, Suling Xu, Shanru Yang · 2022 · International Immunopharmacology
  37. Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer
    Dagyeong Lee, Junyong Choi, Hye Jeong Oh, In‐Hye Ham, Sung Hak Lee, Sachiyo Nomura, Sang‐Uk Han, Hoon Hur · 2022 · Cancer Research and Treatment
  38. Therapeutic Advances in Immunotherapies for Hematological Malignancies
    Ayako Nogami, Koji Sasaki · 2022 · International Journal of Molecular Sciences
  39. Galectin-9 in Gastroenterological Cancer
    Asahiro Morishita, Kyoko Oura, Tomoko Tadokoro, Tingting Shi, Koji Fujita, Joji Tani, Masanori Atsukawa, Tsutomu Masaki · 2023 · International Journal of Molecular Sciences
  40. BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
    Salar Farokhi Boroujeni, Galaxia M. Rodriguez, Kristianne J.C. Galpin, Edward Yakubovich, Humaira Murshed, Dalia Ibrahim, Sara Asif, Barbara C. Vanderhyden · 2023 · Journal of Ovarian Research
  41. Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy
    Yang Li, Beibei Li, Qingchao Wang, Xiangrui Zhang, Qiongqiong Zhang, Xiuman Zhou, Ranran Shi, Yahong Wu, Wenjie Zhai, Zhenzhen Chen et al. · 2024 · Biochemical Pharmacology
  42. Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives
    Sultana Mehbuba Hossain, Carien Carpenter, Michael Roger Eccles · 2024 · International Journal of Molecular Sciences
  43. A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy
    M. Alper Kursunel, Güneş Esendağlı · 2017 · EBioMedicine
  44. Advances and Challenges of CAR T Cells in Clinical Trials
    Astrid Holzinger, Hinrich Abken · 2019 · Recent results in cancer research/Recent Results in Cancer Research
  45. Hyperprogression after immunotherapy
    Waseem Abbas, Ranga Raju Rao, Swati Popli · 2019 · South Asian Journal of Cancer
  46. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome
    Vinicius Araújo Barbosa de Lima, Annie Borch, Morten Hansen, Arianna Draghi, Iben Spanggaard, Kristoffer Staal Rohrberg, Sine Reker Hadrup, Ulrik Lassen, Inge Marie Svane · 2020 · Cytotherapy
  47. Immune involvement of the contralateral hemisphere in a glioblastoma mouse model
    Matheus H. W. Crommentuijn, Sjoerd T. T. Schetters, Sophie A. Dusoswa, Laura J. W. Kruijssen, Juan Jesús García-Vallejo, Yvette van Kooyk · 2020 · Journal for ImmunoTherapy of Cancer
  48. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis
    Lingyun Liu, Jinghai Hu, Yu Wang, Tao Sun, Xiang Zhou, Xinyuan Li, Fuzhe Ma · 2020 · Aging
  49. Emerging immunotherapy targets in lung cancer
    Haohua Zhu, Yu Ying Feng, Xingsheng Hu · 2020 · Chinese Medical Journal
  50. Nanomedicinary evaluation of calotropis procera mediated silver nanoparticle on skin cancer cell line for microbes-front line analysis
    Sumathy Raj, Divya Muthu, R. S. Rimal Isaac, Subhashini Ramakrishnan, E. S. Anooj, Sugumari Vallinayagam · 2021 · Journal of Molecular Structure
  51. Ezrin Modulates the Cell Surface Expression of Programmed Cell Death Ligand-1 in Human Cervical Adenocarcinoma Cells
    Chihiro Tanaka, Takuro Kobori, Mayuka Tameishi, Yoko Urashima, Takuya Ito, Tokio Obata · 2021 · Molecules
  52. Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression
    Xiaoqing Xu, Kun Xie, Bingyu Li, Lijun Xu, Lei Huang, Yan Feng, Chenyu Pi, Jingming Zhang, Tao Huang, Ming Jiang et al. · 2021 · International Immunopharmacology
  53. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
    Lucy Hare, G.A. Amos Burke, Suzanne Dawn Turner · 2021 · Cancers
  54. FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer
    Peter Grell, Simona Bořilová, Pavel Fabián, Iveta Selingerová, David Novak, Petr Müller, Igor Kišš, Rostislav Vyzula · 2023 · Cancers
  55. Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
    Xiaoyue Jiang, Li Li, Yingrui Li, Qin Li · 2019 · Journal of Cancer
  56. Immunophenotype of Vestibular Schwannomas
    Wenya Linda Bi, Saksham Gupta, Yu Mei, Sally Al Abdulmohsen, Alexandra Giantini-Larsen, Prashin Unadkat, Shakti H Ramkissoon, Malak Abedalthagafi, Ian F. Dunn · 2020 · Otology & Neurotology
  57. Secretion of IFN-γ Associated with Galectin-9 Production by Pleural Fluid Cells from a Patient with Extrapulmonary Tuberculosis
    Jingge Zhao, Beata Shiratori, Haorile Chagan Yasutan, Makoto Matsumoto, Toshiro Niki, Michinori Tanaka, Yayoi Takahashi, Osamu Usami, Yugo Ashino, Toshio Hattori · 2017 · International Journal of Molecular Sciences
  58. Colorectal cancer: the immune microenvironment and the gut microbiota – new perspectives, challenges, and opportunities
    Ping Zhou, Wangzheqi Zhang, Yan Liao, Zhiyong Zhai, Sicun Lu, Shuya Jiang, Wei Hu, Wei Gong · 2025 · International Journal of Surgery
  59. Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Hepatocellular Carcinoma
    Takahiro Tomiyama, Shinji Itoh, Norifumi Iseda, Katsuya Toshida, Yukiko Kosai‐Fujimoto, Takahiro Tomino, Takeshi Kurihara, Yoshihiro Nagao, Kazutoyo Morita, Noboru Harada et al. · 2023 · Annals of Surgical Oncology
  60. Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena
    Arya Mariam Roy, Saby George · 2023 · Cancer Drug Resistance
  61. Co-inhibition of TGF-β and PD-L1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance
    Reshmi Nair, Tamsin R.M. Lannagan, René Jackstadt, Anna T. Andrusaite, John J Cole, Caitlin Boyne, Robert J. B. Nibbs, Owen James Sansom, Simon W. F. Milling · 2024 · OncoImmunology
  62. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
    Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, Frank Tacke, Linda Hammerich · 2024 · Seminars in Liver Disease
  63. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
    Bertha Alejandra Martínez-Cannon, Ilaria Colombo · 2024 · Cancer Drug Resistance
  64. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
    Caroline Taylor, Kamai M. Patterson, Devira Friedman, Silvia M. Bacot, Gerald M. Feldman, Tao Wang · 2024 · Cancers
  65. The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma
    Megan Snyder, Zhongyan Wang, Brian Lara, Jocelyn Fimbres, Táchira Pichardo, Sarah A. Mazzilli, Mohammed Muzamil Khan, Vinay Kumar Duggineni, Stefano Monti, David H. Sherr · 2025 · The Journal of Immunology
  66. Enhancing PD-1 blockade in NSCLC: Reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration
    Na Chen, Zhanfeng Li, Heyuan Liu, Aimin Jiang, Liqiang Zhang, Siqi Yan, Wangxiao He, Jingyue Yang, Tianya Liu · 2025 · Bioactive Materials
  67. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment
    Nagaja Capitani, Laura Patrussi, Cosima T. Baldari · 2021 · International Journal of Molecular Sciences
  68. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors
    Kulikowska de Nałęcz, Anna, Ciszak, Lidia, Usnarska-Zubkiewicz, Lidia, Pawlak, Edyta, Frydecka, Irena, Szmyrka, Magdalena, Kosmaczewska, Agata · 2023 · International Journal of Molecular Sciences
  69. The influence of radiation in the context of developing combination immunotherapies in cancer
    Jamie Honeychurch, Tim Illidge · 2017 · Therapeutic Advances in Vaccines and Immunotherapy
  70. The Role of Inflammatory Cytokines in Creating T Cell Exhaustion in Cancer
    Milad Sabzevary‐Ghahfarokhi, Hedayatollah Shirzad, Mahmoud Rafieian‐Kopaei, Mahdi Ghatrehsamani, Mojtaba Shohan · 2018 · Cancer Biotherapy and Radiopharmaceuticals
  71. Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy
    Sadra Behrouzieh, Fateme Sheida, Nima Rezaei · 2021 · Expert Review of Anticancer Therapy
  72. Advances in the immunological microenvironment and immunotherapy of bladder cancer
    Le Meng, Xiangyu Zhu, Xuran Ji, Bowen Wang, Haoxun Zhang, Guoling Zhang, Yue Xue, Chunyang Wang · 2025 · Frontiers in Immunology
  73. Dynamic Evolution of the Tumor Immune Microenvironment in Malignant Tumors and Emerging Therapeutic Paradigms
    Ying Hao Sun, Changjian Shao, Hongtao Duan, Zhaoyang Wang, Shaopeng Xu, Chao Wang, Jiawei Xiu, Jin Liu, Xuejiao Wang, Xin Yao et al. · 2025 · MedComm
  74. Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications
    Hung-Chia Hsieh, Lun-Ling Ling, Wang Yi-Ching · 2026 · Journal of Biomedical Science
  75. A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
    Jie Zhao, Liangfeng Jiang, Haodong Yang, Lan Deng, Xiaoqing Meng, Jian Ding, Sixing Yang, Le Zhao, Wei Xu, Xiaolong Wang et al. · 2022 · mAbs
  76. The Complement System: A Potential Therapeutic Target in Liver Cancer
    Meng Yuan, Li Liu, Chenlin Wang, Yan Zhang, Jiandong Zhang · 2022 · Life
  77. Galectin-9/Tim-3 pathway mediates dopaminergic neurodegeneration in MPTP-induced mouse model of Parkinson’s disease
    Qinyu Peng, Guoxin Zhang, Xiaodi Guo, Lijun Dai, Min Xiong, Zhaohui Zhang, Liam Chen, Zhentao Zhang · 2022 · Frontiers in Molecular Neuroscience
  78. TIM-3 Expression on Dendritic Cells in Colorectal Cancer
    Mei Sakuma, Masanori Katagata, Hirokazu Okayama, Shotaro Nakajima, Katsuharu Saito, Takahiro Sato, Satoshi Fukai, Hideaki Tsumuraya, Hisashi Onozawa, Wataru Sakamoto et al. · 2024 · Cancers
  79. Resistance mechanisms of non-small cell lung cancer and improvement of treatment effects through nanotechnology: a narrative review
    Zhenyu Cao, Jiaqi Zhu, Xingyou Chen, Zhijian Chen, Weixin Wang, Youlang Zhou, Yuchen Hua, Jiahai Shi, Jianle Chen · 2024 · Journal of Thoracic Disease
  80. Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms
    Lijie Wang, Mingyue Shi, Andrew Y. Sung, C Cameron Yin, Yanliang Bai, Mingyi Chen · 2025 · Seminars in Diagnostic Pathology
  81. Predictors of response and resistance to checkpoint inhibitors in solid tumors
    Sanjana Rao, Amy E. Moran, Julie Nicole Graff · 2017 · Annals of Translational Medicine
  82. To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade
    Clement Chung · 2018 · Journal of Oncology Pharmacy Practice
  83. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
    Magalie Dosset, Elodie Lauret Marie Joseph, Thaiz Rivera Vargas, Lionel Apétoh · 2020 · Cells
  84. Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
    Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei · 2021 · Expert Opinion on Biological Therapy
  85. New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer
    Lucy Corke, Adrian Gerold Sacher · 2021 · Current Oncology
  86. The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition
    A. Yu. Kuzevanova, Наталья Владимировна Апанович, Danzan Mansorunov, А. А. Коротаева, Alexander Vasil'evich Karpukhin · 2022 · Biomedicines
  87. Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus
    Hayato Nakamura, Satoru Konnai, Tomohiro Okagawa, Naoya Maekawa, Yamato Sajiki, Kei Watari, Kana KAMITANI, Maya Saito, Yukinari Kato, Yasuhiko Suzuki et al. · 2023 · Journal of Virology
  88. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer
    Liza Cosca Villaruz, George R. Blumenschein, Gregory A. Otterson, Ticiana A.B. Leal · 2023 · Cancer
  89. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma
    Manuela Schmidinger · 2017 · Current Opinion in Urology
  90. PD-L1–Independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy
    Stephen R. Goding, Kyle A. Wilson, Carolyn Rosinsky, Paul Andrew Antony · 2018 · The Journal of Immunology
  91. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy
    Alessia Cimadamore, Marina Scarpelli, Matteo Santoni, Francesco Massari, Francesca Tartari, Roy Cerqueti, Antonio Lopez-beltran B, Liang Cheng C, Rodolfo Montironi · 2019 · Current Drug Metabolism
  92. Mechanisms of Resistance to PD-1 Checkpoint Blockade
    Justin C. Moser, Siwen Hu‐Lieskovan · 2020 · Drugs
  93. Combining radiomics and mathematical modeling to elucidate mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer
    Daryoush Saeed‐Vafa, Rafael Bravo, Jamie Dean, Asmaa El-Kenawi, Nathaniel V. Mon Père, Maximilian A.R. Strobl, Charlie J. Daniels, Olya Stringfield, Mehdi Damaghi, Ilke Tunali et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  94. Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting
    Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Giuseppe Curigliano · 2024 · Cancers
  95. Construction and Preclinical Evaluation of 124I/125I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3
    Jinping Tao, Ziqing Zeng, Chengxue He, Meng Lin, Wenyuan Zhou, Yanan Ren, Xiaopan Ma, Zilei Wang, Jiayue Liu, Dapeng Li et al. · 2024 · Molecular Pharmaceutics
  96. The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy
    Ava Aghakhani, Parmida Sadat Pezeshki, Nima Rezaei · 2024 · Expert Opinion on Investigational Drugs
  97. Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
    Anum Jalil, Melissa Donate, Jane Mattei · 2024 · Cancer Drug Resistance
  98. Emerging Immunotherapy Targets in Early Drug Development
    D. Morchón Araujo, Greta Catani, Oriol Mirallas, Giulia Pretelli, Vicky Sánchez-Pérez, María Vieito, Irene Braña, Ricardo Pujol‐Borrell, Elena Garralda, Alberto Hernando‐Calvo · 2025 · International Journal of Molecular Sciences
  99. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
    Pierangela Sepe, Alessia Mennitto, Francesca Corti, Giuseppe Procopio · 2020 · ImmunoTargets and Therapy
  100. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
    Renrui Zou, Yaomin Wang, F. Ye, X. Zhang, Min Wang, Shiyun Cui · 2021 · Clinical & Translational Oncology